TrialPath
Lupus · New York

Lupus clinical trials in New York

7 recruiting systemic lupus erythematosus studies within range of New York. Click any trial for full eligibility criteria and contact info.

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Recruiting

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

PhasePhase 4
TypeInterventional
Age18 Years – 75 Years
WhereFarmington, Connecticut, United States + 3 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

VIBRANT: VIB4920 for Active Lupus Nephritis

NCT05201469 · Lupus Nephritis
Recruiting

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

PhasePhase 2
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 16 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT07053800 · Lupus Nephritis
Recruiting

The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).

PhasePhase 2
TypeInterventional
Age12 Years – 65 Years
WhereNew York, New York, United States + 15 more
SponsorAutolus Limited
▾Tap for details
Apply

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619 · Lupus Nephritis
Recruiting

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

PhasePhase 2
TypeInterventional
Age5 Years – 17 Years
WhereLoma Linda, California, United States + 43 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104 · Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Recruiting

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).

PhasePhase 1
TypeInterventional
Age18 Years – 74 Years
WherePhoenix, Arizona, United States + 17 more
SponsorAllogene Therapeutics
▾Tap for details
Apply

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Recruiting

Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of care approaches suggests nearly a third of patients accrue retinal damage. Data are needed to accurately weigh the balance between accumulating ocular exposure of HCQ versus the risk of disease flare in a population that may have more inactive disease than younger patients. The purpose of this trial is to address the safety of withdrawal of HCQ in SLE patients \>=55 years old. The central hypothesis is that HCQ can be safely discontinued in stable/quiescent patients assessed by validated disease activity and flare instruments in the context of serologic, cytokine and transcriptomic profiling. Patients will be randomized to either the placebo or active arm and followed every 3 months for one year to assess disease activity and flares.

PhasePhase 3
TypeInterventional
Age55 Years
WhereLos Angeles, California, United States + 11 more
SponsorNYU Langone Health
▾Tap for details
Apply

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

Recruiting

This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.

PhasePhase 2
TypeInterventional
Age16 Years – 70 Years
WhereChicago, Illinois, United States + 3 more
SponsoriCell Gene Therapeutics
▾Tap for details
Apply